Literature DB >> 10363586

Ex vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor-specific Fab immunogene.

Y Ohtake1, J Chen, S Gamou, A Takayanagi, Y Mashima, Y Oguchi, N Shimizu.   

Abstract

The Fab fragment of monoclonal antibody B4G7 against human epidermal growth factor (EGF) receptor was conjugated with cationic poly-L-lysine and the resulting conjugate was further complexed with reporter genes or therapeutic genes. This Fab/DNA complex was designated as "Fab immunogene." The Fab immunogene transfer in vitro was mediated through the EGF receptors in two melanoma cell lines. The frequency of cells expressing beta-galactosidase (beta-Gal) reporter gene was approximately 1%. The induction of suicide effects after Fab immunogene transfer of herpes simplex virus thymidine kinase (TK) or Escherichia coli cytosine deaminase (CD) gene was quite remarkable, and the growth of melanoma cells was inhibited for over 7 days in the presence of ganciclovir (GCV) or 5-fluorocytosine (5-FC). Similarly, when melanoma cells treated in vitro with the Fab immunogene carrying TK or CD were transplanted into the back of nude mouse, subsequent systemic administration of GCV or 5-FC effectively suppressed the growth of tumors, indicating the occurrence of in vivo suicide effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10363586      PMCID: PMC5926092          DOI: 10.1111/j.1349-7006.1999.tb00770.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  31 in total

1.  Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor.

Authors:  S Ozawa; M Ueda; N Ando; O Abe; S Minoshima; N Shimizu
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

Review 2.  Biological response modifiers in melanoma.

Authors:  J A Bridgewater; M E Gore
Journal:  Br Med Bull       Date:  1995-07       Impact factor: 4.291

3.  Increasing epidermal growth factor receptor expression in human melanocytic tumor progression.

Authors:  P E de Wit; S Moretti; P G Koenders; M A Weterman; G N van Muijen; B Gianotti; D J Ruiter
Journal:  J Invest Dermatol       Date:  1992-08       Impact factor: 8.551

Review 4.  Immunotherapy of malignant melanoma.

Authors:  S P Leong
Journal:  Surg Clin North Am       Date:  1996-12       Impact factor: 2.741

5.  Prognostic models in melanoma.

Authors:  A C Halpern; L M Schuchter
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

6.  A novel phorbol ester receptor/protein kinase, nPKC, distantly related to the protein kinase C family.

Authors:  S Ohno; Y Akita; Y Konno; S Imajoh; K Suzuki
Journal:  Cell       Date:  1988-06-03       Impact factor: 41.582

Review 7.  Primary malignant melanoma of the vagina: study of four autopsy cases with ultrastructural findings.

Authors:  K Hasumi; G Sakamoto; H Sugano; T Kasuga; K Masubuchi
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

8.  Human transforming growth factor. Production by a melanoma cell line, purification, and initial characterization.

Authors:  H Marquardt; G J Todaro
Journal:  J Biol Chem       Date:  1982-05-10       Impact factor: 5.157

9.  Production of transforming growth factor-alpha in human tumour cell lines.

Authors:  K Imanishi; K Yamaguchi; M Suzuki; S Honda; N Yanaihara; K Abe
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

10.  Detection of epidermal growth factor receptors and E-cadherins in the basolateral membrane of A431 cells by laser scanning fluorescence microscopy.

Authors:  R Fukuyama; N Shimizu
Journal:  Jpn J Cancer Res       Date:  1991-01
View more
  2 in total

1.  A phase II study of gefitinib in patients with metastatic melanoma.

Authors:  Sapna P Patel; Kevin B Kim; Nicholas E Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Victor G Prieto; Menashe Bar-Eli; Maya Zigler; Andrey Dobroff; Yulia Bronstein; Roland L Bassett; Anna G Vardeleon; Agop Y Bedikian
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

2.  Targeting the EGF receptor for ovarian cancer therapy.

Authors:  Reema Zeineldin; Carolyn Y Muller; M Sharon Stack; Laurie G Hudson
Journal:  J Oncol       Date:  2009-12-28       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.